ERAS insider trading
HealthcareErasca, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Erasca, Inc.
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma. It also develops ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-altered solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-altered solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGRF and RAS/MAPK solid tumors. In addition, the company's products under development include ERAS-801, a central nervous system (CNS)-penetrant EGFR inhibitor for patients with EGFR-altered recurrent glioblastoma (GBM) which is in phase 1 clinical trials; and ERAS-007, an oral inhibitor of ERK1/2 and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It has a license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Company website: www.erasca.com
ERAS insider activity at a glance
FilingIQ has scored 69 insider transactions for ERAS since Jul 20, 2021. The most recent filing in our index is dated Apr 1, 2026.
Across the full history, 22 open-market purchases
and 4 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on ERAS insider trades is 52.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Other Healthcare tickers with recent insider activity
13F funds holding ERAS
Frequently asked
- How many insider trades does FilingIQ track for ERAS?
- FilingIQ tracks 69 Form 4 insider transactions for ERAS (Erasca, Inc.), covering filings from Jul 20, 2021 onwards. 5 of those were filed in the last 90 days.
- Are ERAS insiders net buyers or net sellers?
- Across the full Form 4 history for ERAS, 22 transactions (32%) were open-market purchases and 4 (6%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does ERAS insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is ERAS in?
- Erasca, Inc. (ERAS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $3.75B.
Methodology & sources
Every ERAS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.